

1 **Potential health and economic impact of paediatric vaccination using next generation**

2 **influenza vaccines in Kenya: a modelling study**

3

4 **Authors:** Naomi R Waterlow^{1,†}, Sreejith Radhakrishnan¹, Jeanette Dawa^{2,3}, Edwin van

5 Leeuwen^{1,4}, Philipp Lambach⁵, Joseph Bresee⁶, Marie Mazur⁷, Rosalind M Eggo¹, Mark Jit¹

6

7 ¹ Centre for Mathematical Modeling of Infectious Disease, London School of Hygiene and

8 Tropical Medicine, London WC14 7HT, United Kingdom

9 ² Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya

10 ³ Washington State University - Global Health Kenya, Nairobi, Kenya

11 ⁴ Statistics, Modelling and Economics Department, UK Health Security Agency, London NW9

12 5EQ, United Kingdom

13 ⁵ Immunization Vaccines and Biologicals Department, World Health Organization, Geneva,

14 Switzerland

15 ⁶ The Task Force for Global Health, Decatur, GA, USA

16 ⁷ Ready2Respond, USA

17

18 [†] corresponding author. naomi.waterlow1@lshtm.ac.uk

19 **Abstract:**

20 *Background:* Influenza is a major year-round cause of respiratory illness in Kenya,

21 particularly in children under 5. Current influenza vaccines result in short-term, strain-specific

22 immunity and were found in a previous study not to be cost-effective in Kenya. However,

23 next generation vaccines are in development that may have a greater impact and cost-

24 effectiveness profile.

25

26 *Methods:* We expanded a model previously used to evaluate cost-effectiveness of seasonal
27 influenza vaccines in Kenya to include next generation vaccines by allowing for enhanced
28 vaccine characteristics and multi-annual immunity. We specifically examined vaccinating
29 children under 5 years of age with improved vaccines, evaluating vaccines with
30 combinations of increased vaccine effectiveness, cross protection between strains (breadth)
31 and duration of immunity. We evaluated cost-effectiveness using incremental cost-
32 effectiveness ratios (ICERs) and incremental net monetary benefits (INMBs) for a range of
33 values for the willingness-to-pay (WTP) per DALY averted. Finally, we estimated threshold
34 per-dose vaccine prices at which vaccination becomes cost-effective.

35

36 *Results:* Next generation vaccines can be cost-effective, dependent on the vaccine
37 characteristics and assumed WTP thresholds. Universal vaccines (assumed to provide long-
38 term and broad immunity) are most cost-effective in Kenya across three of four WTP
39 thresholds evaluated, with the lowest median value of ICER per DALY averted (\$263, 95%
40 Credible Interval (CrI): \$-1698, \$1061) and the highest median INMBs. At a WTP of \$623,
41 universal vaccines are cost-effective at or below a median price of \$5.16 per dose (95% CrI:
42 \$0.94, \$18.57). We also show that the assumed mechanism underlying infection-derived
43 immunity strongly impacts vaccine outcomes.

44

45 *Conclusion:* This evaluation provides evidence for country-level decision makers about
46 future next generation vaccine introduction, as well as global research funders about the
47 potential market for these vaccines. Next generation vaccines may offer a cost-effective
48 intervention to reduce influenza burden in low-income countries with year-round seasonality
49 like Kenya.

50

51 **Keywords:** influenza; vaccination; cost-effectiveness; mathematical modelling; next-
52 generation vaccines; health economics

53 Background

54 Influenza is a major cause of respiratory illness in Kenya, particularly in children under 5
55 years old (1,2). Current influenza vaccines result in short-term, strain-specific immunity (3)
56 which is particularly problematic in tropical and subtropical settings where multiple peaks
57 and identifiable year-round activity make it challenging to decide if, who and when to
58 vaccinate, as well as which formulation (northern or southern hemisphere) to use (4–7).
59 Existing vaccines have been evaluated for cost-effectiveness in Kenya, looking at the
60 potential impact of vaccinations in 2010 to 2018 (2). This analysis showed that vaccinating
61 children in Kenya with currently available vaccines was not cost-effective, given current
62 willingness-to-pay thresholds (2). Barriers to cost-effectiveness of influenza vaccination
63 include inconsistent seasonality (with high burden across the year in some years), multiple
64 subtypes of influenza, varying vaccine effectiveness depending on match to circulating
65 influenza strains and the need for annual revaccination(8).

66

67 Many of these obstacles could be addressed by next generation vaccines on the near
68 horizon, with 18 vaccines in clinical trials (10 in phase I, 6 in phase II and 2 in phase III
69 trials), and over 100 in preclinical trials (9,10). Newer technologies are being trialled, for
70 example mRNA vaccines and self-assembling nano-particles, and many of these vaccines
71 aim to overcome the immunodominance of the haemagglutinin (HA) head, instead focusing
72 on more conserved proteins across influenza strains and often aiming to stimulate a T-cell
73 response (9).

74

75 The World Health Organisation (WHO) Preferred Product Characteristics (PPC) (11)
76 describes next generation influenza vaccines in two categories: improved vaccines, which
77 have increased vaccine efficacy (VE) or strain cross-protection (breadth) and which generate
78 immune protection lasting at least a year; and universal vaccines, which have increased
79 efficacy against influenza A phylogenetic HA group viruses and which generate immune

80 protection lasting at least 5 years. These descriptions are based on the likelihood of
81 development in the near to mid future. The US National Institute of Allergy and Infectious
82 Diseases (NIAID) uses similar but slightly varying definitions (12). Such next generation
83 vaccines may hold promising benefits for countries like Kenya, but their potential population
84 impact and cost-effectiveness have yet to be evaluated. Such evaluations could inform
85 country-level decision makers about potential future vaccine introduction, as well as global
86 research funders about the potential market for these vaccines.

87

88 Mathematical models are ideal tools for evaluating their cost-effectiveness, as they allow
89 analysis and comparison of potential hypothetical interventions and strategies. Specifically,
90 transmission dynamic models have the additional advantage of including both direct and
91 indirect benefits of vaccination. This allows evaluation of optimal control strategies including
92 coverage and timing of vaccination campaigns and vaccine characteristics, such as subtype
93 broadness vs efficacy considerations.

94


95 We expand the model previously used to evaluate cost-effectiveness of current influenza
96 seasonal vaccines in Kenya to evaluate the cost-effectiveness of next generation vaccines.

97

98 **Methods**

99 **Overview**

100 We utilise a transmission model from Baguelin *et al.* (2013) (13) that was fitted to Kenya
101 severe acute respiratory illness (SARI) data from 2010 - 2018 by Dawa *et al.* (2013) (2) and
102 extend it to include next generation influenza vaccines with longer durations of immunity,
103 higher efficacy and/or broader sub-type cross-protection (Figure 1). Code is available at
104 https://github.com/NaomiWaterlow/NextGenFlu_Kenya



105

106

107 *Figure 1 - Modelling overview: A) Methods overview, depicting inputs, models and outputs.*

108 *B) Model diagram, including both the epidemic and the vaccination model. Elements in solid*

109 *green are included in both models. Transitions in grey are included only in the epidemic*

110 *model, and transitions in dotted green are included only in the vaccination model. States are:*

111 *Susceptible (S), Exposed (E), Infectious (I) and Recovered (R), and their vaccinated*

112 *counterparts (Sv, Ev1, Ev2, Iv1, Iv2, Rv). v denotes the vaccinated equivalent of the*

113 *compartments. See Table S3 for parameter details. λ_k is the rate of vaccination in age group*

114 *, δ_i is the efficacy by subtype (), ω is vaccine derived immunity waning. The model is run*

115 *separately for each subtype. For the epidemic model, in both vaccinated and unvaccinated*

116 *compartments, susceptibles who are infected with the viral subtype enter the first Exposed*

117 *(E) compartment. They then progress through the E and Infectious (I) compartments. After*

118 *ceasing to be infectious they enter the R compartment, whereupon they cannot be re-*

119 *infected during the same epidemic period. Both the E and I populations consist of two*

120 *compartments, in order to get a gamma distributed waiting time. Each compartment is also*
121 *subdivided by age (i).*

122 Model 1 - Vaccination model

123 The vaccination model (Figure 1B - green compartments) tracks the dynamics of vaccine-
124 induced immunity for each virus subtype without considering prior infection or vaccination
125 status. This is a conservative assumption, assuming vaccination status in the population is
126 unknown and hence people are vaccinated independent of whether they were recently
127 infected or vaccinated. At the time of vaccination the population can be in 1 of 3
128 compartments: Susceptible (S), Susceptible-vaccinated (S_v) and Recovered-vaccinated (R_v)
129 (Figure 1A, green). Vaccination is assumed to be all-or-nothing, with a proportion defined by
130 the efficacy for each subtype entering the R_v compartment where they are immune, and the
131 inverse proportion entering the S_v compartment, where they are susceptible. Waning of
132 vaccination from compartments S_v and R_v occurs exponentially at a rate, ω , determined by
133 the duration of vaccine-induced immunity, returning the population to the S_v compartment.

134

135 We consider scenarios where vaccines have characteristics matching either currently
136 available seasonal influenza vaccines, or next generation vaccines in line with WHO
137 Preferred Product Characteristics (11) (input 1). In the first year, all 0-5 year olds are
138 vaccinated across all vaccine scenarios. Following this, vaccination occurs every x years,
139 calculated as a proportion of the age group, where x is the mean duration of vaccine derived
140 immunity. We generate 5 vaccine scenario examples, corresponding to four categories of
141 Preferred Product Characteristics: current seasonal vaccines, minimally improved vaccines,
142 improved efficacy vaccines, improved breadth vaccines, and universal vaccines (Table 1).
143 We consider vaccines to be either 'matched' or 'mis-matched' to circulating strains each
144 season, and a different efficacy is given in these cases (see supplement for more details).

145

146 *Table 1: Illustrative vaccine scenarios. “Mis-matched seasons” refers to the possibility that*
 147 *the vaccine is not well matched to a particular season’s influenza strain and therefore has*
 148 *reduced efficacy. Immunity duration is assumed to be exponential. All vaccines are given as*
 149 *a campaign, across March, April and May.*

Scenario name	Mis-matched seasons?	Efficacy (Matched/Mis-matched)	Immunity Duration	Coverage	Age-groups vaccinated
No Vaccine	-	-	-	-	-
Current Seasonal Vaccines	Yes	70% / 40%	6 months	50%	All 0-5
Improved vaccines (Minimal)	Yes	70% / 40%	1 year	50%	All 0-5
Improved Vaccines (Efficacy)	Yes	90% / 70%	2 years	50%	All individuals aged 0-5 in the first year of vaccination, followed by age 0, 2 and 4 in subsequent years
Improved Vaccines (Breadth)	No	70% / 70%	3 years	50%	All individuals aged 0-5 in the first year of vaccination, followed by age 0, 2 and 4 in subsequent years
Universal Vaccines	No	90% / 90%	5 years	50%	All individuals aged 0-5 in the first year of

					vaccination, followed by age 0 and 5
--	--	--	--	--	--

150

151 We also run sensitivity analyses where vaccination coverage is 75% for all vaccines,
152 allowing for higher uptake upon new vaccine development (Supplement Section 9).

153

154 We run the model from 1 March 2010, where 1 March each year is considered the start of
155 the southern hemisphere (SH) influenza season. The model runs with given inputs until 31
156 August, as we define 1 September as the start of the Northern Hemisphere (NH) influenza
157 season. VE can differ between seasons to take account of vaccine matched or mis-matched
158 strains. As in Dawa *et al.* (2020) we identify each season's strain as matched or mis-
159 matched to vaccination based on published VE data (Table S1) and assume that a VE \geq
160 50% is a matched vaccine, and $< 50\%$ is a mis-matched vaccine. Following the NH season,
161 the population size is updated (see Supplement section 1), and ageing of the population
162 occurs, to allow for a build up of immunity in the relevant age groups. The model runs from 1
163 March 2010 to 28 February 2019. We model transmission of each influenza subtype
164 separately (A(H1N1), A(H3N2), B) to allow different vaccine efficacies across subtypes. We
165 assume all individuals are born susceptible to infection.

166

167 This vaccination model outputs the proportion of the population that is vaccinated, and of this
168 the proportion that is immunised for each subtype every week over the modelled period.

169 Model 2 - Epidemic Model

170 We model the 11 subtype-specific epidemic time periods that were identified and fitted in
171 Dawa *et al.* (2020) (Figure 2A). As in Dawa *et al.* (2020) we define influenza epidemics to
172 start at the first week of a time period consisting of " ≥ 2 successive weeks where the

173 proportion of subtype-specific test-positive cases was greater than the average weekly
174 proportion during the entire study” (Figure 2A). Where an epidemic was previously defined to
175 last less than 8 months, we follow it for the full 8 months to allow capturing the
176 consequences of a slower epidemic progression as the result of vaccination. At the start of
177 each epidemic the proportion of the population in the S , S_v and R_v compartments is taken
178 from the output of the vaccination model, in the matching week and for the relevant virus
179 subtype. Vaccine efficacy is split into NH and SH time frames as in the vaccination model.
180 For each epidemic we run an independent transmission model (with structure of Figure 1B)
181 with the estimated transmission rate, susceptibility for three age groups (≤ 14 , 15-49, 50+),
182 initial number of infections and the probability of identifying an influenza-positive patient
183 within the catchment population for 3 age groups (<1 , 1-5, 6+) from Dawa *et al.* (2020).
184 Influenza immunity is assumed to be leaky. Supplement section 2 contains the model
185 equations, parameters and values.
186
187 For key transmission parameters (transmission rate, susceptibility, number of infections at
188 the start of the season, number of imports and ascertainment rates), we use the estimated
189 values by Dawa *et al.* 2020 for each of the 11 strain/subtype-specific peaks in influenza
190 activity identified between 2010 - 2018 (input 2). The parameter values for each
191 strain/subtype-specific peak are estimated independently, using the *fluEvidenceSynthesis* R
192 package. We also use the same age groups (<1 , 1-5, 6-14, 15-19, 20-49 and ≥ 50 years
193 old) contact patterns and population sizes. For more details see Dawa *et al.* (2020) .
194
195 In our main analysis we assume that the previous season’s vaccination has no effect on the
196 proportion of people who have infection-derived immunity at the start of the next season.
197 This is supported by statistical analyses indicating that susceptibility at the start of each

198 season (based on the model fit in Dawa *et al.* (2020)) is not strongly dependent on infections
199 in the previous season (Supplement section 4). To explore the possibility that there is some
200 dependency, we run sensitivity analyses with two different assumptions on changes in
201 susceptibility (Supplement section 9).

202 Model 3 - Background FOI

203 To characterise influenza epidemiology in Kenya, we use weekly numbers of hospitalised
204 patients with SARI from 2010-2018 from the Kenyan National SARI surveillance system
205 (input 3). Data from a subset of 5 large hospitals that have a bed capacity of over 200 and a
206 well-established surveillance system in place is used. The case definition of SARI was a
207 hospitalised patient with acute illness onset presenting with fever or cough. A random
208 sample of these patients underwent virological analysis to identify the presence or absence
209 of influenza. For further details and data access, see Dawa *et al.* (2020).

210

211 To account for infections in the inter-epidemic periods, we include a background rate of
212 infection with a Poisson distribution with shape parameter $\Lambda_{i,k}$, fitted to the weekly observed
213 cases in each age group and of each subtype across all inter-epidemic periods. We then
214 calculate the weekly number of background infections per age group, i , and subtype, k ,
215 across the whole time period:

216

$$\text{Background Infections}_{t,i,k} = \sum_{i=1}^{n=6} \Lambda_{i,k} * (\text{sus}_{t,i,k} / \text{asc}_{i,k})$$

217

218 Where $\text{sus}_{t,i,k}$ is the proportion susceptible each week (t) for age group i and influenza
219 subtype s outputted from the vaccination model, $\text{asc}_{i,k}$ is the mean ascertainment rate by
220 age group as estimated in the Dawa *et al.* (2020) paper.

221 Model 4 - Economic analyses

222 We estimate the incremental cost-effectiveness of each of the vaccine scenarios in Table 1
223 (compared to no vaccination), following WHO recommendations for economic evaluations of
224 vaccines (14). The analytic time horizon used in the economic analyses is the same as the
225 epidemiological model (2010-2019 inclusive), except that life years lost due to death are
226 counted until the full normal life expectancy. Information on input costs used in these
227 analyses (input 4) can be found in the Supplement section 8. We adopt a societal
228 perspective on costs, and both costs and health outcomes are discounted at 3% per annum,
229 with 0% discounting for health outcomes in a sensitivity analysis. All costs (except vaccine
230 costs) are expressed in terms of 2019 USD and costs from other years are adjusted using
231 Kenya gross domestic product (GDP) deflator values (15) before calculating cost-
232 effectiveness measures.

233

234 Uncertainty is captured using probabilistic sensitivity analysis. This is done by drawing 1000
235 random samples per vaccine scenario of the total number of influenza infections generated
236 from 2010 to 2019 by all virus subtypes across all age groups and charting disease and
237 hospitalisation outcomes for each infection. Adopting the same approach as Dawa *et al.*
238 (2020), we use a decision tree (Supplement section 8) to project health-related outcomes
239 associated with influenza infections. Samples of probability parameters are drawn from a
240 beta distribution (16) whose shape parameters were calculated first by fitting the mean and
241 95% confidence intervals for each probability parameter (drawn from the literature) to a beta
242 distribution (2).

243

244 We further divide symptomatic infections into mild (upper respiratory tract infections, URTI)
245 or severe (lower respiratory tract infections, LRTI) illness. Patients with mild illness will
246 receive medical attention at outpatient clinics and eventually recover. Severely ill patients go

247 on to be hospitalised, and further progress to recover from illness or die. The mean durations
248 of influenza-associated illness and length of hospital stay are assumed to be 4 days (17,18).

249

250 A range of influenza-related healthcare utilisation events such as seeking medical care at
251 outpatient clinics, hospitalisation as inpatients and purchase of over-the-counter medication
252 are assumed to incur healthcare costs. To capture uncertainty around these costs, random
253 samples of cost parameters are drawn from a gamma distribution (16). Direct medical costs
254 include the price of influenza vaccines, assumed to be \$3 per dose, and vaccine wastage,
255 assumed to be 15% (2). Healthcare related costs include transportation costs for hospital
256 visits to seek medical care for influenza-associated illness or for influenza vaccination.
257 Similarly, indirect costs include lost wages and childcare costs due to influenza-related
258 illness (see supplement section 8, and Figure 1 and Tables 2 and 3 in Dawa *et al.*, (2020) for
259 parameter values and references).

260

261 For health outcomes, we calculate disability-adjusted life years (DALYs) using disability
262 weights for mild URTI, moderate and severe LRTI and death (GBD, 2019). In contrast to
263 Dawa *et al.* (2020), no age-weighting of DALYs is done, as this is no longer recommended
264 (14).

265

266 We determine cost-effectiveness of vaccination scenarios by calculating median incremental
267 cost-effectiveness ratios (ICERs) per DALY averted and median incremental net monetary
268 benefits (INMBs) across all ten years for each vaccine scenario compared to the no
269 vaccination scenario. The most cost-effective scenario is the one with the lowest ICER value
270 and the highest INMB value. In the absence of locally-determined cost-effectiveness
271 thresholds for health interventions in Kenya, ICERs are evaluated against a WHO 'best buy'
272 threshold of \$100 per DALY averted in LMICs as well as cost-effectiveness thresholds
273 derived using two broad approaches - marginal productivity thresholds calculated by the
274 University of York (19) and those based on global analyses by the Commission for

275 Macroeconomics and Health (20). While results using four WTP thresholds (Table 2) are
276 presented in the main paper, details of the full range of thresholds used and corresponding
277 results are presented in the supplement (section 8). These thresholds are also used to
278 calculate vaccine prices at or below which a vaccination scenario is deemed cost-effective.

279

280 All results presented in the main text are calculated using discounted costs and DALYs. In
281 sensitivity analyses, undiscounted costs are also used. We also analyse the effect of
282 changing the vaccine price to \$1.50, \$6 and \$10 per dose.

283

284 *Table 2: Selected willingness to pay (WTP) thresholds used in this study*

WTP threshold (USD)	Description*	Reference
100	WHO best buy	(21)
623	45% Kenya pc GDP (2015)	(19)
1912.65	1x Kenya pc GDP (2019)	(22)
5737.95	3x Kenya pc GDP (2019)	(22)

285 *pc GDP - per capita gross domestic product


286 Results

287 Cases averted and doses used

288

289 While all modelled vaccine types increased the proportion of the population with some
290 immunity, *Universal vaccines* resulted in the highest levels of immunity across the whole
291 period (Supplemental section 7). In addition, this resulting immunity was generated with
292 fewer vaccine doses due to slower waning, with a total of 14 million vaccine doses used for
293 the *Universal vaccine* scenario over the whole time period. The same number of vaccines

294 were used for *Improved vaccine (breadth)* scenarios, 19 million for *Improved vaccine*
295 (*efficacy*) scenarios and 30 million for the *Current seasonal vaccines* and the *Improved*
296 *vaccines (Minimal)* scenario.
297



298
299 *Figure 2: A) Number of weekly reported cases during epidemic and inter-epidemic*
300 *periods. Epidemic periods are highlighted in brown, and periods used to estimate the*
301 *background force of infection are shown in grey. B) Model projections of cumulative number*
302 *of infections (median and 95% CrI) by vaccine scenario.*

303

304 The high immunity from *Universal* vaccines translated into the biggest projected reduction in
305 cumulative infections across the 10 year period with a median total of 66% of infections
306 averted (95% Credible Interval (CrI) 56%-74%) as compared to the no vaccination scenario.
307 This compared to the *Improved (Efficacy)* of 57% (95% CrI 47 - 67%), *Improved (Breadth)* of
308 51% (95% CrI 42%- 61%), *Improved (Minimal)* 41% (95% CrI 33% - 49%) and *Current*
309 *seasonal* of 29% (95% CrI 23% - 35%) infections averted. The mean R_0 of influenza across

310 epidemics was 2.2 (range 1.2 - 6.7, Supplement section 8 for further details) and across
311 vaccination scenarios the average number of cases averted per vaccine dose ranged from
312 0.33 to 2.6.


313

314 Cost-effectiveness

315

316 Programmes using *Universal* and *Improved (Breadth)* vaccines incurred the lowest total
317 vaccine purchase and administration costs across the entire period, assuming per-dose
318 vaccine costs are the same for all vaccines (\$3), because they required the fewest doses.
319 These amounted to a median total value of \$78.86 million (95% CrI: \$60.96, \$125.18 (in
320 millions)), compared to \$108.54 million for *Improved (Efficacy)* and \$167.91 million for both
321 *Improved (Minimal)* and *Current seasonal* (Supplement section 8). After accounting for these
322 costs and the costs of travel to seek vaccination, programmes using universal vaccines
323 incurred the lowest total societal costs (direct medical, healthcare-related and indirect costs)
324 and thereby incremental total costs, compared to when no vaccination was conducted
325 (Figure 3A). Median discounted incremental total costs for *Universal* vaccines were \$27.67
326 million (95% CrI: \$-174.38, \$78.21 (in millions)). In contrast, median discounted incremental
327 costs were higher for all *Improved* vaccines and highest for *Current seasonal* vaccines
328 (\$128.64 million (95% CrI \$35.62, \$228.43 (in millions)) (Supplement section 8).

329



330

331 *Figure 3: A) Mean (with 95% CrI) discounted incremental total costs (in millions of USD) vs.*

332 *mean (with 95% CrI) reduction in number of cases (in millions) for each vaccine (2010 –*

333 *2019). B) Boxplot of ICER per DALY averted for each vaccine (2010 - 2019). Horizontal lines*

334 *represent different willingness-to-pay thresholds per DALY averted. C) Boxplot of INMB (in*

335 *millions of USD) (2010 to 2019) at four selected thresholds of WTP per DALY averted.*

336

337 None of the vaccines were cost-effective at the WHO best buy threshold of \$100 per DALY

338 averted when evaluating cost-effectiveness using discounted costs and DALYs (Figure 3).

339 While there was overlap between uncertainty ranges of ICER values calculated for all five

340 vaccines, *Universal* vaccines were cost-effective across three of the four WTP thresholds
341 evaluated in this study, with a median ICER per DALY averted of \$263 (95% CrI: \$-1698,
342 \$1061) (Figure 3B). Similarly, *Improved (breadth)* vaccines were cost-effective across three
343 of four WTP thresholds with a median ICER value of \$422 per DALY averted, while
344 *Improved (Efficacy)* vaccines had a median ICER value of \$626, being cost-effective across
345 two of four thresholds. In contrast, *Current seasonal* vaccines had a median ICER value of
346 \$2764 per DALY averted, being cost-effective only at a WTP threshold of 3 times the 2019
347 per capita GDP of Kenya of approximately \$5738 (Figure 3B, Supplement section 8). Thus,
348 median ICER values for *Improved (Breadth)*, *Improved (Efficacy)* and *Current seasonal*
349 vaccines were 1.60, 2.38 and 10.51 times higher than for *Universal* vaccines, respectively.

350

351 Similarly, *Universal* vaccines had the highest median INMB values across all WTP
352 thresholds (Figure 3C). At a threshold of \$623 (45% of Kenya's 2019 per capita GDP), the
353 median INMB value of *Universal* vaccines (\$39.6 million) was 2.29 times higher than that of
354 *Improved (Breadth)* (\$17.26 million) vaccines (Supplement section 8). At this threshold,
355 *Universal* vaccines had a high probability (>75%) of being cost-effective, at or below a
356 median price of \$5.16 per vaccine dose (95% CrI: \$0.94, \$18.57) (Table 3, Fig. S7,
357 supplement section 8). Calculated threshold per-dose vaccine prices were consistently
358 higher for *Universal* vaccines across all WTP thresholds. *Universal* vaccines had median
359 INMB values 4.21 times higher than that of *Current seasonal* vaccines (\$134.63 million) at a
360 WTP threshold of \$5738.

361

362 *Table 3: Median (and 95% CrI) values of threshold per-dose vaccine prices (2019 USD) at or*
363 *below which each vaccination scenario is cost-effective, calculated using discounted costs*
364 *and DALYs, at four selected thresholds of willingness-to-pay per DALY averted. These are*
365 *calculated while including a median vaccine administration cost of \$1.31 per dose (gamma*
366 *distributed).*

Vaccine	WHO best buy (\$100)	45% per capita GDP (\$623)	1x per capita GDP (\$1913)	3x per capita GDP (\$5738)
Current seasonal	-0.87 (-3.74, 1.85)	-0.14 (-2.92, 2.63)	1.54 (-1.43, 5.79)	6.51 (1.54, 16.66)
Improved (minimal)	-0.58 (-3.48, 3.29)	0.45 (-2.49, 4.38)	2.86 (-0.69, 8.77)	9.97 (3.52, 23.2)
Improved (breadth)	0.98 (-2.05, 10.85)	3.77 (0.03, 14.02)	10.4 (4.05, 25.4)	29.47 (13.83, 64.04)
Improved (efficacy)	0.46 (-2.42, 8.38)	2.67 (-0.71, 10.9)	7.99 (2.69, 19.89)	23.31 (10.78, 50.57)
Universal	1.59 (-1.51, 14.2)	5.16 (0.94, 18.57)	13.67 (5.99, 31.68)	37.8 (18.74, 79.06)

367 *pc GDP - per capita gross domestic product

368

369 In our sensitivity analyses, increased coverage of vaccination made only slight differences to
370 the cost-effectiveness of any of the vaccines across the different WTP thresholds evaluated
371 (supplement, section 9). The number of cases averted per vaccine dose was slightly lower
372 than in the 50% coverage scenario, ranging from 0.31 - 2.16. In addition, we found that
373 assumptions around susceptibility had a large impact on impact and cost-effectiveness. If we
374 assumed that greater reduction in infections in one season increased susceptibility in the
375 next season, then vaccines were less impactful and cost-effective (see supplement section
376 10 for details).

377

378 Discussion

379 Our study indicates that next generation vaccines are likely to have much greater impact and
380 an improved cost-effectiveness profile than currently available influenza vaccines. This is
381 true even for incrementally improved vaccines with slightly greater breadth or duration.
382 These are evidenced by the scale of reduction in influenza infections and improvements in
383 cost-effectiveness measures, particularly for universal vaccines. Universal vaccines result in
384 the most substantial reduction in influenza infections utilising the least vaccine doses,
385 averting 66% of infections compared to no vaccination. In contrast, our model predicts that
386 current vaccines avert only 29% of infections, while even improved (minimal) vaccines avert
387 41% of infections. Similarly, ICER values are higher for improved (1.60 to 2.38 times) and
388 current seasonal (10.51 times) vaccines than for universal vaccines. Universal vaccines also
389 have the highest INMB values - 2.29 times higher than Improved (breadth) vaccines at a
390 WTP threshold of \$623, and 4.21 times higher than current seasonal vaccines at a WTP
391 threshold of \$5738, the only threshold at which current vaccines are cost-effective. Thus our
392 results suggest that universal vaccines result in the highest immunity per vaccine dose and
393 subsequently, the least number of infections, as well as having the most favourable cost-
394 effectiveness profile among all the vaccines evaluated.

395

396 Our conclusions are influenced by vaccine dose costs and cost-effectiveness thresholds. We
397 assumed that vaccine per-dose costs are the same for all vaccines (\$3), which is unlikely to
398 be true. More advanced vaccines may cost more per dose. As a comparison, SARS-Cov-2
399 AstraZeneca vaccines, which were sold without profit, cost between \$2.15 and \$5.25 per
400 dose, compared to mRNA SARS-CoV-2 vaccines costing \$14.70 to \$23.50 per dose (23).
401 Nevertheless, our estimates of the threshold per-dose vaccine price (prices at or below
402 which vaccination programs are cost-effective) suggest that universal vaccines are cost-
403 effective even when priced higher than current seasonal or improved vaccines and
404 irrespective of the WTP threshold. At the same time, we find that improved vaccines can

405 also be cost-effective at comparatively low WTP thresholds and result in fewer influenza
406 cases than currently available seasonal vaccines, even if priced higher per dose. The
407 development and use of universal vaccines are very likely to benefit low-and-middle-income
408 countries which may only be willing or able to pay less for health benefits than more
409 advanced economies. However, universal vaccines are unlikely to be immediately available
410 for widespread use, but improved vaccines offer substantial value as an achievable and
411 satisfactory alternative to current influenza vaccines, especially since these may be available
412 in the near future.

413

414 Our analyses demonstrate the importance of assumed cost-effectiveness thresholds when
415 determining whether health interventions are cost-effective or not. Kenya does not have an
416 official cost-effectiveness threshold, but Dawa *et al.* (2020) reported that vaccination with
417 current seasonal influenza vaccines in Kenya had a low probability of being cost-effective
418 given WTP thresholds of 1-51% of per capita GDP. To address uncertainty around
419 thresholds, we used a wide range of values ranging from extremely low WHO “best buys”
420 threshold reserved for evaluating some of the most cost-effective programmes that WHO
421 has ever evaluated (21), to very high 1-3 times GDP per capita thresholds representing the
422 potential value of human capital associated with disability (24). Like Dawa *et al.*, we find that
423 current vaccines are cost-effective only at a very high threshold of 3 times the per capita
424 GDP of Kenya and at a maximum threshold price of \$6.51 per dose, which is much lower
425 than prices at which most influenza vaccines are available in the US (25) or UK (26).
426 Conversely, both universal and improved influenza vaccines are cost-effective at lower
427 thresholds.

428

429 A key strength of our epidemiological model is the direct incorporation of vaccine-derived
430 immunity waning over multiple years, with ageing of the population, which is required to
431 evaluate next generation vaccines with benefits that last several years. This contrasts to
432 many seasonal vaccination models where vaccine-derived immunity is not tracked across

433 seasons (2,13). In contrast with the marked annual seasonality of influenza in temperate
434 regions (27), influenza epidemics in Kenya do not have a regular seasonal pattern, with
435 substantial transmission in between epidemics, which we included by separately modelling
436 the inter-epidemic periods. However we used a relatively simple approach for this and we do
437 not capture indirect effects of vaccination between epidemics. In addition, while we include 3
438 influenza subtypes (AH1N1, A H3N2 and B), we do not allow for any interaction between
439 these subtypes, which may contribute to the dynamics of transmission (28–33). However, as
440 our modelling is based on fitted models, this should not have major impacts on our economic
441 analysis. Therefore the main practical disadvantage is that we are unable to investigate
442 vaccines with different efficacies within the influenza B viruses.

443

444 Country decisions to invest in health interventions can be influenced by considerations other
445 than cost-effectiveness (34), for example due to competing options for implementation or
446 due to widespread vaccine hesitancy. Whilst our modelling indicates that next generation
447 vaccines can be cost-effective, their implementation will be competing against other public
448 health interventions. In Kenya, separate studies have shown both rotavirus and
449 pneumococcal childhood vaccination to be cost effective, with between \$25 and \$59 (35)
450 and \$38 (36) per DALY averted respectively, and programmes covering these vaccines have
451 been introduced. However, these estimates are substantially lower than for even the
452 universal influenza vaccines calculated here. Equity in vaccine distribution (37) is also a key
453 consideration for vaccine programme implementation. The availability of financing options
454 such as from Gavi, the Vaccine Alliance (38), is also important, but Kenya is already starting
455 to transition out of Gavi support.

456

457 Our study has a number of other limitations. We have assumed that vaccination occurs
458 independent of current vaccine status, meaning that individuals can receive multiple
459 vaccinations and therefore some vaccinations will be ‘wasted’ on individuals already
460 immune. This is a conservative assumption, likely making the vaccine scenarios appear less

461 cost-effective, and is more likely to have an effect at higher coverage levels. It is also
462 recommended that children between 6 months and 8 years of age, or those who have only
463 ever received one dose, should receive two vaccine doses at least 4 weeks apart (39,40).
464 Administration of a second vaccine dose will incur additional costs for vaccine purchase,
465 transport and administration, although these additional costs may be off-set by vaccinating
466 independent of vaccine status. In reality, there may also be challenges to administer
467 vaccines twice due to limited access. We also do not consider adverse vaccine reactions
468 (40,41) in our DALY calculations. These would influence cost-effectiveness and vaccine
469 threshold prices, particularly at lower cost-effectiveness thresholds.

470

471 Immune protection to influenza virus infection and vaccination are poorly understood and we
472 found that assumptions on infection-derived immunity have a large impact on incidence and
473 resulting cost-effectiveness estimates. However, such assumptions could not be empirically
474 informed, because in this setting the previous season does not have an impact on estimated
475 susceptibility levels in the following season and our sensitivity analyses with different
476 infection-susceptibility assumptions show different behaviour than observed for current
477 seasonal vaccines. Therefore our main analysis presents the most likely assumptions.
478 Another important consideration is the potential population-level effects of universal vaccines
479 on vulnerability to newer influenza virus variants. Previous mathematical modelling studies
480 suggest that universal vaccines can prevent the development of cross-protective immunity
481 developed through natural infection. In the absence of sufficiently high vaccination coverage,
482 it was thus suggested that universal vaccines can increase the risks of emergence of
483 vaccine escape variants that could cause influenza pandemics (42,43). These studies
484 suggest that combining administration of seasonal and universal vaccines may help to
485 mitigate these risks (42), a strategy which we have not explored in our study.

486 Conclusions

487

488 Our study provides the first formal evaluation incorporating both direct and indirect (herd)
489 protection, of the effectiveness and cost-effectiveness of a range of next generation
490 influenza vaccines meeting WHO PPCs. In doing so it bolsters the case for investing in
491 development of these vaccines, while highlighting the benefits to be derived from improved
492 vaccines. This provides proof-of-principle for similar studies to be conducted in other LMICs,
493 so that a global picture of potential demand for these vaccines can be built.

494 List of Abbreviations

495

496 CrI – Credible Interval

497 DALY – disability-adjusted life years

498 E – Exposed

499 GDP – gross domestic product

500 HA - haemagglutinin

501 I – infectious

502 ICER – incremental cost-effectiveness ratio

503 INMB – incremental net monetary benefits

504 LMIC – lower middle-income countries

505 LRTI – lower respiratory tract infections

506 NH - Northern Hemisphere

507 NIAID – National Institute of Allergy and Infectious Diseases

508 PPC – Preferred product characteristics

509 R – recovered

- 510 Rv – Recovered-vaccinated
- 511 S - Susceptible
- 512 SARI – severe acute respiratory illness
- 513 SH - Southern Hemisphere
- 514 Sv – Susceptible-vaccinated
- 515 URTI – upper respiratory tract infections
- 516 USD – US Dollars
- 517 VE – Vaccine efficacy
- 518 WHO – World Health Organisation
- 519 WTP – Willingness-to-pay

520 **Declarations**

521 *Ethics Approval*

522 Not applicable.

523 *Consent for publication*

524 Not applicable

525 *Availability of data and materials*

526 The datasets analysed during the current study are available in the Supplement of Dawa *et*

527 *al.* (2020). ([https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-020-01687-](https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-020-01687-7#Sec18)

528 [7#Sec18](https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-020-01687-7#Sec18))

529 All code is available at https://github.com/NaomiWaterlow/NextGenFlu_Kenya.

530

531 *Competing Interests*

532 The authors declare that they have no competing interests.

533

534 *Funding*

535 This work was funded by the Wellcome Trust, Centers for Disease Control and
536 Prevention and Taskforce for Global Health via the grant “Modeling cost-
537 effectiveness of improved seasonal influenza vaccines in two exemplar countries”.
538 JB was funded by PIVI and CDC. EvL and RME were also supported by the National
539 Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in
540 Modelling and Health Economics, a partnership between UK HSA, Imperial College
541 London, and LSHTM (grant number NIHR200908) and EvL was also supported by
542 the European Union's Horizon 2020 research and innovation programme - project
543 EpiPose (101003688).

544

545 *Authors contributions*

546 RME, MJ, JB and MM contributed to the conception of the project. RME, MJ, JD,
547 NRW, SR and EvL contributed to the design of the work. NRW, SR, JD and EvL
548 contributed to the analysis of the work. NRW, SR, JD, EvL, JB, MM, PL, RME and
549 MJ contributed to the interpretation of the data. NRW, SR and JD contributed to the
550 creation of the new software in the work. NRW and SR drafted the manuscript and
551 NRW, SR, JD, EvL, JB, MM, PL, RME and MJ reviewed and edited the manuscript.

552

553 *Acknowledgments*

554 We would like to acknowledge the advice received from Sandra Chaves, Marc-Alain
555 Widdowson and Gideon Emukule.

556 **References**

557

- 558 1. McMorro ML, Emukule GO, Njuguna HN, Bigogo G, Montgomery JM, Nyawanda B, et
559 al. The Unrecognized Burden of Influenza in Young Kenyan Children, 2008-2012. PLoS

- 560 ONE. 2015 Sep 17;10(9):e0138272.
- 561 2. Dawa J, Emukule GO, Barasa E, Widdowson MA, Anzala O, van Leeuwen E, et al.
562 Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic
563 transmission modelling. *BMC Med*. 2020 Aug 20;18:223.
- 564 3. Gomez Lorenzo MM, Fenton MJ. *Immunobiology of Influenza Vaccines*. Chest. 2013
565 Feb;143(2):502–10.
- 566 4. Hirve S. Seasonal Influenza Vaccine Use in Low and Middle Income Countries in the
567 Tropics and Subtropics [Internet]. World Health Organization; 2015 [cited 2022 Jul 27] p.
568 99. Available from: <https://www.who.int/publications-detail-redirect/9789241565097>
- 569 5. Lambach P, Alvarez AMR, Hirve S, Ortiz JR, Hombach J, Verweij M, et al.
570 Considerations of strategies to provide influenza vaccine year round. *Vaccine*. 2015 Nov
571 25;33(47):6493–8.
- 572 6. Hirve S, Lambach P, Paget J, Vandemaele K, Fitzner J, Zhang W. Seasonal influenza
573 vaccine policy, use and effectiveness in the tropics and subtropics - a systematic
574 literature review. *Influenza Other Respir Viruses*. 2016 Jul;10(4):254–67.
- 575 7. Vaccine in tropics and subtropics [Internet]. [cited 2022 Aug 17]. Available from:
576 [https://www.who.int/teams/global-influenza-programme/vaccines/vaccine-in-tropics-and-](https://www.who.int/teams/global-influenza-programme/vaccines/vaccine-in-tropics-and-subtropics)
577 [subtropics](https://www.who.int/teams/global-influenza-programme/vaccines/vaccine-in-tropics-and-subtropics)
- 578 8. Matheka DM, Mokaya J, Maritim M. Overview of influenza virus infections in Kenya:
579 past, present and future. *Pan Afr Med J*. 2013 Apr 8;14:138.
- 580 9. Universal Influenza Vaccine Technology Landscape | CIDRAP [Internet]. [cited 2022 Apr
581 5]. Available from: [https://ivr.cidrap.umn.edu/universal-influenza-vaccine-technology-](https://ivr.cidrap.umn.edu/universal-influenza-vaccine-technology-landscape)
582 [landscape](https://ivr.cidrap.umn.edu/universal-influenza-vaccine-technology-landscape)
- 583 10. Moore KA, Ostrowsky JT, Kraigsley AM, Mehr AJ, Bresee JS, Friede MH, et al. A
584 Research and Development (R&D) roadmap for influenza vaccines: Looking toward the
585 future. *Vaccine*. 2021 Oct 29;39(45):6573–84.
- 586 11. WHO Preferred Product Characteristics for Next-Generation Influenza Vaccines
587 [Internet]. [cited 2022 Jan 6]. Available from: [https://www.who.int/publications-detail-](https://www.who.int/publications-detail-redirect/9789241512466)
588 [redirect/9789241512466](https://www.who.int/publications-detail-redirect/9789241512466)
- 589 12. Erbeling EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, et al. A
590 Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and
591 Infectious Diseases. *J Infect Dis*. 2018 Jul 2;218(3):347–54.
- 592 13. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing
593 Optimal Target Populations for Influenza Vaccination Programmes: An Evidence
594 Synthesis and Modelling Study. *PLoS Med* [Internet]. 2013;10(10). Available from:
595 <http://researchonline.lshtm.ac.uk/1273063/>
- 596 14. WHO. WHO guide for standardization of economic evaluations of immunization
597 programmes [Internet]. 2nd ed. Geneva PP - Geneva: World Health Organization; 2019
598 p. 137–137. Available from: <https://apps.who.int/iris/handle/10665/329389>
- 599 15. Inflation, GDP deflator (annual %) - Kenya | Data [Internet]. Available from:
600 <https://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG?locations=KE>
- 601 16. Briggs AH, Claxton K, Sculpher MJ. *Decision modelling for health economic evaluation*.
602 Oxford: Oxford University Press; 2006. 237 p. (Oxford handbooks in health economic
603 evaluation).
- 604 17. Carrat F, Vergu E, Ferguson NM, Lemaître M, Cauchemez S, Leach S, et al. Time Lines
605 of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies.
606 *Am J Epidemiol*. 2008 Apr 1;167(7):775–85.
- 607 18. Emukule GO, Ndegwa LK, Washington ML, Paget JW, Duque J, Chaves SS, et al. The
608 cost of influenza-associated hospitalizations and outpatient visits in Kenya. *BMC Public*
609 *Health*. 2019 May;19(3):1–10.
- 610 19. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and
611 middle-income countries: a novel approach and evidence from cross-country data. *BMJ*
612 *Glob Health*. 2018 Nov;3(6):e000964.
- 613 20. Loganathan T, Ng CW, Lee WS, Hutubessy RCW, Verguet S, Jit M. Thresholds for
614 decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines

- 615 in Malaysia. Health Policy Plan. 2018 Mar 1;33(2):204–14.
- 616 21. Organization WH. Tackling NCDs: ‘best buys’ and other recommended interventions for
617 the prevention and control of noncommunicable diseases [Internet]. Geneva PP -
618 Geneva: World Health Organization; 2017 p. 25–25. Available from:
619 <https://apps.who.int/iris/handle/10665/259232>
- 620 22. GDP per capita (current US\$) - Kenya | Data [Internet]. [cited 2022 Jun 13]. Available
621 from:
622 [https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?end=2020&locations=KE&start=](https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?end=2020&locations=KE&start=2018)
623 [2018](https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?end=2020&locations=KE&start=2018)
- 624 23. Light DW, Lexchin J. The costs of coronavirus vaccines and their pricing. J R Soc Med.
625 2021 Nov 1;114(11):502–4.
- 626 24. Tan-Torres Edejer T, Baltussen RMPM, Adam T, Acharya A, Evans DB, Murray CJL.
627 Making choices in health □: WHO guide to cost-effectiveness analysis [Internet]. World
628 Health Organization; 2003 [cited 2022 Jul 27]. Available from:
629 <https://apps.who.int/iris/handle/10665/42699>
- 630 25. VFC | Current CDC Vaccine Price List | CDC [Internet]. 2022 [cited 2022 Jul 7]. Available
631 from: [https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-](https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html)
632 [list/index.html](https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html)
- 633 26. Medicinal forms | Influenza vaccine | Drugs | BNF content published by NICE [Internet].
634 [cited 2022 Jul 7]. Available from: [https://bnf.nice.org.uk/drugs/influenza-](https://bnf.nice.org.uk/drugs/influenza-vaccine/medicinal-forms/)
635 [vaccine/medicinal-forms/](https://bnf.nice.org.uk/drugs/influenza-vaccine/medicinal-forms/)
- 636 27. Lofgren E, Fefferman NH, Naumov YN, Gorski J, Naumova EN. MINIREVIEW Influenza
637 Seasonality: Underlying Causes and Modeling Theories. J Virol. 2007;81(11):5429–36.
- 638 28. Andreasen V, Lin J, Levin SA. The dynamics of cocirculating influenza strains conferring
639 partial cross-immunity. J Math Biol. 1997 Aug;35(7):825–42.
- 640 29. Sonoguchi T, Naito H, Hara M, Takeuchi Y, Fukumi H. Cross-Subtype Protection in
641 Humans During Sequential, Overlapping, and/or Concurrent Epidemics Caused by
642 H3N2 and H1N1 Influenza Viruses. J Infect Dis. 1985 Jan;151(1):81–8.
- 643 30. Koutsakos M, Illing PT, Nguyen THO, Mifsud NA, Crawford JC, Rizzetto S, et al. Human
644 CD8+ T cell cross-reactivity across influenza A, B and C viruses. Nat Immunol. 2019
645 May;20(5):613–25.
- 646 31. Yang W, Lau EHY, Cowling BJ. Dynamic interactions of influenza viruses in Hong Kong
647 during 1998–2018. Viboud C, editor. PLOS Comput Biol. 2020 Jun;16(6):e1007989–
648 [e1007989](https://doi.org/10.1371/journal.pcbi.1007989).
- 649 32. Lin J, Andreasen V, Levin SA. Dynamics of influenza A drift: the linear three-strain
650 model. Math Biosci. 1999 Nov;162(1–2):33–51.
- 651 33. Waterlow NR, Flasche S, Minter A, Eggo RM. Competition between RSV and influenza:
652 limits of modelling inference from surveillance data. Epidemics. 2021 Mar 26;100460.
- 653 34. Jit M. Informing Global Cost-Effectiveness Thresholds Using Country Investment
654 Decisions: Human Papillomavirus Vaccine Introductions in 2006–2018. Value Health.
655 2021 Jan 1;24(1):61–6.
- 656 35. Sigei C, Odaga J, Mvundura M, Madrid Y, Clark AD. Cost-effectiveness of rotavirus
657 vaccination in Kenya and Uganda. Vaccine. 2015 May 7;33:A109–18.
- 658 36. Ayieko P, Griffiths UK, Ndiritu M, Moisi J, Mugoya IK, Kamau T, et al. Assessment of
659 Health Benefits and Cost-Effectiveness of 10-Valent and 13-Valent Pneumococcal
660 Conjugate Vaccination in Kenyan Children. PLoS ONE. 2013 Jun 24;8(6):e67324.
- 661 37. Vaccine equity [Internet]. [cited 2022 Jul 8]. Available from:
662 <https://www.who.int/campaigns/vaccine-equity>
- 663 38. Gavi, the Vaccine Alliance [Internet]. [cited 2022 Jul 8]. Available from:
664 <https://www.gavi.org/>
- 665 39. CDC. Children & Influenza (Flu) [Internet]. Centers for Disease Control and Prevention.
666 2021 [cited 2022 Jul 7]. Available from: <https://www.cdc.gov/flu/highrisk/children.htm>
- 667 40. Influenza vaccine | Drugs | BNF content published by NICE [Internet]. [cited 2022 Jul 7].
668 Available from: <https://bnf.nice.org.uk/drugs/influenza-vaccine/>
- 669 41. Seasonal Influenza Vaccine Safety: A Summary for Clinicians | CDC [Internet]. 2021

- 670 [cited 2022 Jul 7]. Available from:
671 https://www.cdc.gov/flu/professionals/vaccination/vaccine_safety.htm
672 42. Arinaminpathy N, Riley S, Barclay WS, Saad-Roy C, Grenfell B. Population implications
673 of the deployment of novel universal vaccines against epidemic and pandemic influenza.
674 J R Soc Interface. 2020 Mar;17(164):20190879.
675 43. Subramanian R, Graham AL, Grenfell BT, Arinaminpathy N. Universal or Specific? A
676 Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against
677 Conventional, Strain-Matched Vaccines. Regoes RR, editor. PLOS Comput Biol. 2016
678 Dec 15;12(12):e1005204.